EGFR and neoplasm: To investigate the potential role of EGFR in limiting trametinib efficacy, we reduced the expression of EGFR by shRNA in the CAL33 and HSC3 cell lines (Fig. S2A) and then evaluated the sensitivity of tumor cells to trametinib in vitro and in vivo.